Stay updated on PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.

Latest updates to the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe Publications section text was updated to clarify that publications are provided voluntarily by the person entering information about the study, and the revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the government funding lapse notice that previously warned users the site information may not be up to date or processed during funding gaps. The notice also advised users to check other sources for operating status.SummaryDifference0.4%

- Check62 days agoChange DetectedDifference0.4%

- Check91 days agoChange DetectedUpgrade to v3.2.0 with a prominent operating-status notice and links to status pages; indicates continuing government funding fluctuations may affect site responsiveness.SummaryDifference2%

- Check98 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.